The LSD1 inhibitors which are under clinical trial mainly focus on treatment of AML and MDS, and only one LSD1 inhibitor, CC-90011 is undergoing clinical trials for NHL therapy. This evidence concerns the gene KDM1A and myelodysplastic syndrome.